Bavarian, BioMedica Call Vaccine Patent Truce
Foes no longer, Bavarian Nordic A/S and Oxford BioMedica PLC have entered cross-licensing agreements as part of a global settlement ending allegations that BioMedica's experimental cancer drug filches Bavarian's patented vaccine...To view the full article, register now.
Already a subscriber? Click here to view full article